Geoffrey D Barnes, MD, MSc
Associate Professor of Internal Medicine
Medical School
[email protected]

Available to mentor
Geoffrey D Barnes, MD, MSc
Associate Professor
  • About
  • Links
  • Qualifications
  • Center Memberships
  • Research Overview
  • Recent Publications
    • Manage Your Profile
    About

    Dr. Barnes is a cardiologist and vascular medicine specialist. His research focuses on developing, implementing, and evaluating antithrombotic stewardship efforts to improve the care of patients with thrombotic conditions and/or those who use anticoagulant medications. He serves as co-director for the Michigan Anticoagulation Quality Improvement Initiative (MAQI2) and as co-director for the Michigan Program on Value Enhancement (MPrOVE). His research is funded by the NIH, AHRQ, and Blue Cross-Blue Shield of Michigan. He serves in leadership roles with several national and International organizations, including the Anticoagulation Forum, American College of Cardiology, and International Society on Thrombosis and Hemostasis. He also serves as the program director for the University of Michigan Vascular Medicine fellowship training program.

    Links
    Qualifications
    • Cardiovascular Medicine Fellowship
      University of Michigan, Internal Medicine/Cardiovascular Medicine, 2014
    • Vascular Medicine Fellowship
      University of Michigan, Internal Medicine/Cardiovascular Medicine, 2014
    • Internal Medicine Chief Residency
      University of Michigan, Internal Medicine, 2011
    • Internal Medicine Residency
      University of Michigan, Internal Medicine, 2010
    • MS
      University of Michigan, 2015
    • MD
      University of Michigan, 2007
    • BS
      Washington University in St. Louis, 2003
    Center Memberships
    • Center Member
      Center for Bioethics and Social Sciences in Medicine
    • Center Member
      Precision Health Initiative
    • Center Member
      Institute for Healthcare Policy and Innovation
    • Center Member
      Samuel and Jean Frankel Cardiovascular Center
    Research Overview

    Anticoagulation therapy
    Venous Thromboembolism
    Implementation Science
    Quality Improvement
    Health systems engineering
    Shared decision-making

    Recent Publications See All Publications
    • Journal Article
      A Comparison of Outcomes With Apixaban, Rivaroxaban, and Warfarin for Atrial Fibrillation and/or Venous Thromboembolism
      Schaefer JK, Errickson J, Kong X, Ali MA, Chipalkatti N, Haymart B, Kaatz S, Krol GD, Sood SL, Froehlich JB, Barnes GD. JACC: Advances, 2025 May 1; 4 (5): DOI:10.1016/j.jacadv.2025.101714
    • Journal Article
      A Web-Based Tool to Perform a Values Clarification for Stroke Prevention in Patients With Atrial Fibrillation: Design and Preliminary Testing Study.
      Dorsch MP, Flynn AJ, Greer KM, Ganai S, Barnes GD, Zikmund-Fisher B. JMIR Cardio, 2025 Apr 11; 9: e67956 DOI:10.2196/67956
      PMID: 40215398
    • Journal Article
      New targets for antithrombotic medications: seeking to decouple thrombosis from hemostasis
      Barnes GD. Journal of Thrombosis and Haemostasis, 2025 Apr 1; 23 (4): 1146 - 1159. DOI:10.1016/j.jtha.2024.12.003
      PMID: 39675564
    • Journal Article
      Effectiveness of shared decision making strategies for stroke prevention among patients with atrial fibrillation: cluster randomized controlled trial
      Ozanne EM, Barnes GD, Brito JP, Cameron KA, Cavanaugh KL, Greene T, Jackson EA, Montori VM, Steinberg BA, Witt DM, Noseworthy P, Passman RS, Kansal P, Crossley G, Roden DM, Christensen JT, Ariotti A, Jones AE, Bardsley T, Wu C, Fagerlin A, McCarty M, Beck K, McCarthy S, Hargraves I, LaVecchia C, Hartasanchez S, Pershing M, Williams S, Gahagan H, King J, Delaney R, Kolomaya A. BMJ, 2025 Jan 1; DOI:10.1136/bmj-2024-079976
      PMID: 39788611
    • Journal Article
      Evaluation of patient and encounter decision aid interventions for atrial fibrillation: Baseline characteristics of the RED-AF study - A Randomized Controlled Trial
      Nayak T, Christensen JT, Bardsley T, Barnes GD, Cameron KA, Passman R, Kansal P, Witt DM, Cavanaugh KL, Fagerlin A, Ozanne EM. Contemporary Clinical Trials, 2025 Jan 1; 148: DOI:10.1016/j.cct.2024.107773
      PMID: 39645031
    • Journal Article
      Heterogeneity in American and European Peripheral Artery Disease Guidelines on Non-statin Lipid-Lowering Therapy and Rivaroxaban
      Zarghami M, Rashedi S, Piazza G, Gerhard-Herman MD, Barnes GD, Bikdeli B. Thrombosis and Haemostasis, 2025 Jan 1; DOI:10.1055/a-2510-6370
      PMID: 39775759
    • Journal Article
      Performance of an Electronic Health Record–Based Automated Pulmonary Embolism Severity Index Score Calculator: Cohort Study in the Emergency Department
      Joyce E, McMullen J, Kong X, O'Hare C, Gavrila V, Cuttitta A, Barnes GD, Greineder CF. JMIR Medical Informatics, 2025 Jan 1; 13: DOI:10.2196/58800
    • Journal Article
      Pulmonary Embolism Response Teams
      Caceres J, Barnes GD. Medical Clinics of North America, 2025 Jan 1; DOI:10.1016/j.mcna.2025.01.005
    Featured News & Stories prescription pad drawn
    Health Lab
    Reducing dose of popular blood thinners may limit risk of future bleeding
    For people taking the popular blood thinners rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis), after having a blood clot, a reduced dose may limit the future risk of bleeding as well as hospital visits, a Michigan Medicine-led study suggests.
         prescription pad blue yellow sketch
    Health Lab
    Risk of clots, stroke from incorrect blood thinner dosing reduced using online dashboard
    Doctors and pharmacists treating people with blood thinners can now reduce the rate of inappropriate dosing — as well as blood clots and strokes that can result from it — using an electronic patient management system.
         person at counter with medicine brown bottle and pills
    Health Lab
    Most blood thinner dosing problems happen after initial prescription
    More than two-thirds of those people take a type of blood thinner called a direct oral anticoagulant. These DOACs, such as rivaroxaban (brand name Xarelto) and apixaban (brand name Eliquis), are under- or over-prescribed in up to one in eight patents. These prescribing issues can have life-threatening consequences, and they most often occur after a provider writes the initial prescription, according to a study led by Michigan Medicine.
         Top LGBTQ+ docs
    Research News
    Dr. Geoff Barnes named on the 2024 Top LGBTQ+ Doctors List!
    Dr. Geoff Barne's named on the 2024 Top LGBTQ+ Doctors List